Metformin: historical overview.
Bailey CJ.
Diabetologia. 2017 Sep;60(9):1566-1576. doi: 10.1007/s00125-017-4318-z. Epub 2017 Aug 3.
Metformin in patients with type 2 diabetes and kidney disease: a systematic review.
Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK.
JAMA. 2014 Dec 24-31;312(24):2668-75. doi: 10.1001/jama.2014.15298.
Metformin-associated lactic acidosis: Current perspectives on causes and risk.
DeFronzo R, Fleming GA, Chen K, Bicsak TA.
Metabolism. 2016 Feb;65(2):20-9. doi: 10.1016/j.metabol.2015.10.014. Epub 2015 Oct 9.
Metformin-associated lactic acidosis.
Fadden EJ, Longley C, Mahambrey T.
BMJ Case Rep. 2021 Jul 8;14(7):e239154. doi: 10.1136/bcr-2020-239154.
Metformin: Past, Present, and Future.
Chaudhary S, Kulkarni A.
Curr Diab Rep. 2024 Jun;24(6):119-130. doi: 10.1007/s11892-024-01539-1. Epub 2024 Apr 3.
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Salpeter S, Greyber E, Pasternak G, Salpeter E.
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD002967. doi: 10.1002/14651858.CD002967.pub2.
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE.
Cochrane Database Syst Rev. 2010 Apr 14;2010(4):CD002967. doi: 10.1002/14651858.CD002967.pub4.
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE.
Cochrane Database Syst Rev. 2010 Jan 20;(1):CD002967. doi: 10.1002/14651858.CD002967.pub3.
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Salpeter S, Greyber E, Pasternak G, Salpeter E.
Cochrane Database Syst Rev. 2003;(2):CD002967. doi: 10.1002/14651858.CD002967.
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Salpeter S, Greyber E, Pasternak G, Salpeter E.
Cochrane Database Syst Rev. 2002;(2):CD002967. doi: 10.1002/14651858.CD002967.
